


12-03-04

DFW



EXPRESS MAIL NO.: EV380370385US

DATE MAILED: December 1, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of:
Vanitha RAMAKRISHNAN, et al.

Appl. No. 10/724,274

Filed: November 26, 2003

For: CHIMERIC AND HUMANIZED
ANTIBODIES TO $\alpha 5 \beta 1$ INTEGRIN THAT
MODULATE ANGIOGENESIS

Art Unit: 1644

Examiner: Not Yet Assigned

Attorney Docket: 05882.0178.NPUS01

Confirmation No.: 1255

Information Disclosure Statement

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The PTO did not receive the following
listed item(s) Item # 14-22

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed;
- ☐ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - c. Before the mailing date of a first Office Action on the merits;
 - ☐ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- ☐ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained

in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

37 C.F.R. § 1.97(e)(2), or

- ☐ c. Attached is our Check No. _____ in the amount of _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.

- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. - _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.


The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number **05882.0145.NPUS00**.

Respectfully submitted,


Date: December 1, 2004


Adam K. Whiting (Reg. No. 44,400)

HOWREY SIMON ARNOLD & WHITE, LLP
2941 Fairview Park Drive
Box 7
Falls Church, VA 2204201
(650) 463-8133

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449 	ATTY. DOCKET NO. 05882.0178.NPUS01	APPLICATION NO. 10/724,274
	APPLICANT RAMAKRISHNAN, et al.	
	FILING DATE November 26, 2003	GROUP Not yet assigned

U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	1.	4,935,496	06-19-90	Kudo				
	2.	4,946,778	08-07-90	Ladner				
	3.	5,502,167	03-26-96	Waldmann				
	4.	5,536,814	07-16-96	Ruoslathi				
	5.	5,558,864	09-24-96	Bendig				
	6.	5,639,641	06-17-97	Pedersen				
	7.	5,693,493	12-02-97	Robinson				
	8.	5,698,417	12-16-97	Robinson				
	9.	5,705,154	01-06-98	Dalie				
	10.	5,750,078	05-12-98	Shitara				
	11.	5,770,403	06-23-98	Abrams				
	12.	5,922,676	07-13-99	Pasqualini				
	13.	2002/0172675 A1	07-05-02	Varner				
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	14.	WO 95/14714	06-01-95	PCT				
	15.	WO 95/14772	06-01-95	PCT				
	16.	WO 95/22618	08-24-95	PCT				
	17.	WO 97 33887	09-18-97	PCT				
	18.	EP 0 896 002	02-10-99	EP				
	19.	WO 99/55913	11-04-99	PCT				
	20.	WO 99/58139	11-18-99	PCT				
	21.	WO 01/11086	02-15-01	PCT				
	22.	WO 02/079492	10-10-02	PCT				

<p align="center">LIST OF REFERENCES CITED BY APPLICANT</p> <p align="center"><i>(Use several sheets if necessary)</i></p> <p align="center">PTO FORM 1449</p> 	<p>ATTY. DOCKET NO.</p> <p>05882.0178.NPUS01</p>	<p>APPLICATION NO.</p> <p>10/724,274</p>
	<p>APPLICANT</p> <p>RAMAKRISHNAN, et al.</p>	
	<p>FILING DATE</p> <p>November 26, 2003</p>	<p>GROUP</p> <p>Not yet assigned</p>

OTHER REFERENCES		
<i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
23.	Argraves et al., J. Biol. Chem. 261(28):12922-12924 (1986)	
24.	Hackett, R., et al., 1996, Dermatotoxicology. 5 th Edition. Ed. By F.B. Marzulli and H.I. Maibach. Hemisphere Publishing Corp., Washington, D.C	
25.	Proulx et al., "Effect of quiescence on integrin $\alpha 5 \beta 1$ expression in human retinal pigment epithelium" Molecular Vision 9:473-481 (2003)	
26.	Pytela et al., Cell 40: 191-198 (1985)	
27.	Ryan, S.J., The Development of an Experimental Model of Subretinal Neovascularization in Disciform Macular Degeneration," Transactions of the American Ophthalmological Society 77: 707-745 (1979)	
28.	Ryan, S.J., "Subretinal Neovascularization: Natural History of an Experimental Model," Archives of Ophthalmology 100: 1804-1809 (1982)	
29.	Thorpe et al., "Monoclonal Antibodies in Biological Clinical Applications," 475-506 (1985)	
30.	Tolentino, M.J., et al., "Angiography of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody and Dextran in Experimental Choroidal Neovascularization," Archives of Ophthalmology 118: 78-84 (2000)	
31.	Varner et al., "Antagonists of vascular cell integrin alpha 5 beta 1 inhibit angiogenesis," Circulation 98(17) Supp. 'S', 4166-4166 (Oct. 1998)	
32.	Varner et al., "Integrins and cancer," Current Opinion in Cell Biology, 8(5): 724-30 (1996).	
33.	Varner et al., "Tumor angiogenesis and the role of vascular cell integrin $\alpha 5 \beta 1$," Important Advances in Oncology, (1996), 69-87.	